Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
An erratum to this article was published (Lancet Diabetes Endocrinol, Feb 2026 ↗)
Authors' conclusion
All tested survodutide doses were tolerated, and dose-dependently reduced bodyweight.
Study context
- Population
- Adults aged 18–75 years, BMI ≥27 kg/m², without diabetes; 43 centres in 12 countries386 treated
- Participants
- 387 adults
- Comparison
- Once-weekly subcutaneous survodutide vs placebo
- 0.6 mgn = 77
- 2.4 mgn = 78
- 3.6 mgn = 77
- 4.8 mgn = 77
- Placebon = 77reference
- Primary endpoint
- Percentage change in bodyweight from baseline
- Follow-up
- Week 46
Methodological detailsdouble-blind, placebo-controlled, dose-finding, phase 2, multicentre, 233 (60.4%) of 386 completed the 46-week treatment period
- Double-blind
- Placebo-controlled
- Dose-finding
- Phase 2
- Multicentre
- 233 (60.4%) of 386 completed the 46-week treatment period
Primary result
As reported in the abstract
Mean % change in bodyweight · baseline to week 46
0.6 mg
−6.2%
mean · 95% CI −8.3–-4.1
2.4 mg
−12.5%
mean · 95% CI −14.5–-10.5
3.6 mg
−13.2%
mean · 95% CI −15.3–-11.2
4.8 mg
−14.9%
mean · 95% CI −16.9–-13.0
Placebo
−2.8%
mean · 95% CI −4.9–-0.7
Safety
Adverse events
Gastrointestinal adverse events
- Adverse events: survodutide doses pooled (n=309)
Original publication
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. Published 5 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →